AM1172 (an endocannabinoid analog) lowers melanoma cell viability but is cytotoxic to healthy cells: an in vitro isobolographic study

AM1172 is tested as an endocannabinoid analog for melanoma, both alone and in combination with standard chemotherapy drugs, to assess antiproliferative and cytotoxic effects in vitro. Experiments used human melanoma cell lines (A375, FM55P, SK-MEL 28, FM55M2) and combined AM1172 with docetaxel, paclitaxel, mitoxantrone, or cisplatin. Isobolographic analysis found additive drug interactions for most AM1172 combinations, with one reported case of synergy (AM1172 plus paclitaxel in primary A375 cells). AM1172 also showed significant cytotoxicity when used alone on healthy cell types, including human melanocytes (HEMa-LP) and human keratinocytes (HaCaT). The study concludes AM1172 is unlikely to work as a stand-alone chemotherapeutic, but may have potential as an adjuvant to existing chemotherapy in melanoma cell systems.